La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BioGend Therapeutics Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Not At All Concerned With BioGend Therapeutics' (GTSM:6733) Cash Burn Situation

Mar 24

We Think BioGend Therapeutics (GTSM:6733) Can Afford To Drive Business Growth

Dec 10

AMMINISTRATORE DELEGATO

BioGend Therapeutics non ha un CEO, o non abbiamo dati su di loro.

BioGend Therapeutics Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

BioGend Therapeutics Co., Ltd., Annual General Meeting, May 28, 2024

BioGend Therapeutics Co., Ltd., Annual General Meeting, Jun 08, 2021

Recent updates

Second quarter 2024 earnings released: NT$0.28 loss per share (vs NT$0.26 loss in 2Q 2023)

BioGend Therapeutics Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

BioGend Therapeutics Co., Ltd. Announces Hsinchu Factory Pass the Domestic Medical Device Quality Management System (Qms) Manufacturing License

First quarter 2024 earnings released

Full year 2023 earnings released: NT$1.30 loss per share (vs NT$1.79 loss in FY 2022)

BioGend Therapeutics Co., Ltd., Annual General Meeting, May 28, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: NT$0.36 loss per share (vs NT$0.51 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: NT$0.26 loss per share (vs NT$0.33 loss in 2Q 2022)

Full year 2022 earnings released: NT$1.79 loss per share (vs NT$1.37 loss in FY 2021)

Third quarter 2022 earnings released: NT$0.50 loss per share (vs NT$0.39 loss in 3Q 2021)

Third quarter 2022 earnings released: NT$0.50 loss per share (vs NT$0.39 loss in 3Q 2021)

Second quarter 2022 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2021)

First quarter 2022 earnings released: NT$0.43 loss per share (vs NT$0.47 loss in 1Q 2021)

Third quarter 2021 earnings released: NT$0.39 loss per share (vs NT$0.48 loss in 3Q 2020)

First quarter 2021 earnings released: NT$0.47 loss per share (vs NT$0.42 loss in 1Q 2020)

Here's Why We're Not At All Concerned With BioGend Therapeutics' (GTSM:6733) Cash Burn Situation

BioGend Therapeutics Co., Ltd., Annual General Meeting, Jun 08, 2021

Full year 2020 earnings released: NT$1.67 loss per share (vs NT$2.01 loss in FY 2019)

New 90-day low: NT$27.75

New 90-day low: NT$31.20

We Think BioGend Therapeutics (GTSM:6733) Can Afford To Drive Business Growth

New 90-day low: NT$38.75

Third quarter 2020 earnings released: NT$0.48 loss per share

AMMINISTRATORE DELEGATO